Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD33xCD3 BsAb in Pediatric Relapsed/Refractory AML
NCT05077423Phase 1Terminated
- Sponsor
- Y-mAbs Therapeutics, Inc.
- Start
- May 2022
- Primary completion
- Dec 2022
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of huCD33-BsAb in acute myeloid leukemia (AML), sponsored by Y-mAbs Therapeutics, Inc. Primary endpoints: Occurrence of dose limiting toxicities at 28 days and Occurrence of Adverse Events at 52 weeks. Started May 2022; status: terminated.
02
Drugs
huCD33-BsAb
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05077423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05077423.